Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive;Number of Participants With IL28B Genotype rs12979860 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced;Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Naive;Number of Participants With IL28B Genotype rs8099917 by METAVIR Liver Inflammation Grade and HCV RNA Genotype: Treatment-Experienced;Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Naive;Number of Participants With IL28B Genotype rs12979860 by Gender: Treatment-Experienced;Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Naive;Number of Participants With IL28B Genotype rs8099917 by Gender: Treatment-Experienced;Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Naive;Number of Participants With IL28B Genotype rs12979860 by Ethnic Origin: Treatment-Experienced;Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Naive;Number of Participants With IL28B Genotype rs8099917 by Ethnic Origin: Treatment-Experienced;Mean Body Weight by IL28B Genotype rs12979860: Treatment-Naive;Mean Body Weight by IL28B Genotype rs12979860: Treatment-Experienced;Mean Body Weight by IL28B Genotype rs8099917: Treatment-Naive;Mean Body Weight by IL28B Genotype rs8099917: Treatment-Experienced;Mean Body Mass Index (BMI) by IL28B Genotype rs12979860: Treatment-Naive;BMI by IL28B Genotype rs12979860: Treatment-Experienced;BMI by IL28B Genotype rs8099917: Treatment-Naive;BMI by IL28B Genotype rs8099917: Treatment-Experienced;Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Naive;Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype: Treatment-Experienced;Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Naive;Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype: Treatment-Experienced;Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive;Mean HCV RNA Level by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced;Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive;Mean HCV RNA Level by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced;Mean Alanine Aminotransferase (ALT) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive;Mean ALT Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced;Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive;Mean ALT Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced;Mean Aspartate Aminotransferase (AST) Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive;Mean AST Ratio by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced;Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive;Mean AST Ratio by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced;Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Naive;Mean Platelet Count by IL28B Genotype rs12979860 and HCV RNA Genotype: Treatment-Experienced;Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Naive;Mean Platelet Count by IL28B Genotype rs8099917 and HCV RNA Genotype: Treatment-Experienced;Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Naive;Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Region: Treatment-Experienced;Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Naive;Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Region: Treatment-Experienced;Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]);Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]);Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]);Number of Participants With IL28B Genotype rs12979860 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]);Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]);Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]);Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]);Number of Participants With IL28B Genotype rs8099917 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]);Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Naive;Number of Participants With IL28B Genotype rs12979860 by IL28B Genotype rs8099917 Category: Treatment-Experienced;Number of Participants With Inosine Triphosphatase (ITPA) Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Naive;Number of Participants With ITPA Genotype rs7270101 by ITPA Genotype rs1127354 Category: Treatment-Experienced;Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Naive;Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Region: Treatment-Experienced;Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Naive;Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Region: Treatment-Experienced;Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]);Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]);Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]);Number of Participants With ITPA Genotype rs1127354 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]);Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 1 of 2 [G1, G2, G3]);Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Naive (Table 2 of 2 [G4, Other, Total]);Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 1 of 2 [G1, G2, G3]);Number of Participants With ITPA Genotype rs7270101 by HCV RNA Genotype and Country: Treatment-Experienced (Table 2 of 2 [G4, Other, Total]);Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype;Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response in the First 12 Weeks of Treatment and HCV RNA Genotype;Number of Participants With IL28B Genotype rs12979860 by Type of Virological Response at End of Treatment and HCV RNA Genotype;Number of Participants With IL28B Genotype rs8099917 by Type of Virological Response at End of Treatment and HCV RNA Genotype;Number of Participants With IL28B Genotype rs12979860 by Overall Virological Response Type and HCV RNA Genotype;Number of Participants With IL28B Genotype rs8099917 by Overall Virological Response Type and HCV RNA Genotype;Number of Participants With ITPA Genotype rs1127354 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype;Number of Participants With ITPA Genotype rs7270101 by Incidence of Hemoglobin Drop During Prior Treatment and HCV RNA Genotype;Number of Participants With ITPA Genotype rs1127354 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype;Number of Participants With ITPA Genotype rs7270101 by Erythropoietin Use During Prior Treatment and HCV RNA Genotype